Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18144250 | 0.88 | NFE2L2 (0.58) | RAB9AMAPTAHRALDH1A1KDM4E | |
| SCHEMBL18144249 | 0.88 | NFE2L2 (0.58) | RAB9AMAPTAHRALDH1A1KDM4E | |
| SCHEMBL19449762 | 0.86 | CA1 (0.48) | CA1CA2CA7CA9CA12 | |
| SCHEMBL14047382 | 0.85 | CA1 (0.46) | CA1CA2CA7CA9CA12 | |
| SCHEMBL16626095 | 0.84 | RAB9A (0.51) | CA1CA2CA7CA9CA12 | |
| SCHEMBL7154424 | 0.83 | CA1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL17943274 | 0.82 | ACHE (0.65) | CA1CA2CA7CA9CA12 | |
| SCHEMBL16626130 | 0.82 | CA4 (0.54) | CA1CA2CA7CA9CA12 | |
| SCHEMBL18144043 | 0.81 | MAPT (0.37) | CA1CA2CA7CA9CA12 | |
| SCHEMBL18144046 | 0.81 | MAPT (0.37) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10042258-B2 | Composition for forming a resist upper-layer film and method for producing a semiconductor device using the composition | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2018-08-07 | — | — | US | disclosed |
| US-20170205711-A1 | COMPOSITION FOR FORMING A RESIST UPPER-LAYER FILM AND METHOD FOR PRODUCING A SEMICONDUCTOR DEVICE USING THE COMPOSITION | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-07-20 | — | — | US | disclosed |
| US-8946438-B2 | Benzamides, production thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946438-B2 | Benzamides, production thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946438-B2 | Benzamides, production thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20140187539-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-03 | — | — | US | disclosed |
| US-20140187539-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-03 | — | — | US | disclosed |
| US-20140187539-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-03 | — | — | US | disclosed |
| US-8735579-B2 | Benzamides, production thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-8735579-B2 | Benzamides, production thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| WO-2006016039-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2006-02-16 | — | — | WO | disclosed |
| EP-1549621-A1 | FLUORINATED PHENYL-NAPHTHALENYL-UREA COMPOUNDS AS INHIBITORS OF CYTOKINES INVOLVED IN INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-6872726-B2 | Fluorinated di-aryl urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-03-29 | — | — | US | disclosed |
| US-20050032797-A1 | Fluorinated di-aryl urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| WO-2004096798-A2 | DERIVATIVES OF 2-ACYLAMINO-4-PHENYLTHIAZOLE, PREPARATION METHOD THEREOF AND USE OF SAME AS CHEMOKINE ANTAGONISTS | SANOFI-AVENTIS (FR) | 2004-11-11 | — | — | WO | disclosed |
| US-20040077647-A1 | Cytokine inhibitors, antiinflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004014870-A1 | FLUORINATED PHENYL-NAPHTHALENYL-UREA COMPOUNDS AS INHIBITORS OF CYTOKINES INVOLVED IN INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| US-6376710-B2 | INSECTICIDES, NEMATODICIDES, MITICIDES | SUMITOMO CHEMICAL CO., LTD. (JP) | 2002-04-23 | — | — | US | disclosed |
| US-20010041740-A1 | Amidine compounds and their use as pesticides | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2001-11-15 | — | — | US | disclosed |
| EP-1138668-A2 | Amidine compounds and their use as pesticides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077647-A1 | Cytokine inhibitors, antiinflammatory agents | IL1B, IL1A, TNF | CA1 3301/4885CA2 3554/4885CA7 4126/4885 |
| US-20050032797-A1 | Fluorinated di-aryl urea compounds | IL1B, MPO, IL1A | CA1 4401/4885CA2 4503/4885CA7 4089/4885 |
| US-20140187539-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | HRH2, HRH1, HRH4 | CA1 3202/4885CA2 292/4885CA7 320/4885 |
| US-20010041740-A1 | Amidine compounds and their use as pesticides | DDT, CNR1, PRMT1 | CA1 505/4885CA2 571/4885CA7 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.